US 12,275,800 B2
Anti-coagulation factor XI antibodies
Zhu Chen, Warren, NJ (US); Kenneth Ellsworth, Cranbury, NJ (US); James Milligan, Sevierville, TN (US); Elizabeth Oldham, Santa Clara, CA (US); Dietmar Seiffert, Lawrence Township, NJ (US); Bianka Prinz, Lebanon, NH (US); Vaishnavi Ganti, Foster City, CA (US); and Mohammad Tabrizifard, Moranga, CA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US); and Adimab, LLC, Lebanon, NH (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US); and Adimab, LLC, Lebanon, NH (US)
Filed on Apr. 18, 2023, as Appl. No. 18/302,033.
Application 16/864,559 is a division of application No. 15/619,620, filed on Jun. 12, 2017, granted, now 10,676,536, issued on Jun. 9, 2020.
Application 18/302,033 is a continuation of application No. 16/864,559, filed on May 1, 2020, granted, now 11,661,460.
Claims priority of provisional application 62/349,888, filed on Jun. 14, 2016.
Prior Publication US 2023/0287141 A1, Sep. 14, 2023
Int. Cl. C07K 16/36 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/36 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); A61K 2039/58 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A method for therapeutic or prophylactic treatment of a thromboembolic disorder or disease in a subject comprising:
administering to the subject an effective amount of an antibody or antigen binding fragment comprising:
(i) six complimentary determining regions (CDRs) of an anti-FXI antibody of the αFXI-18611 family,
wherein the six CDRs comprise
(a) CDR1, CDR2, and CDR3 of the heavy chain (HC) having the amino acid sequence shown in SEQ ID NO: 37 or 39; and
(b) CDR1, CDR2, and CDR3 of the light chain (LC) having the amino acid sequence shown in SEQ ID NO: 26.